DMARDs, a Guide to Monitoring Requirements

Tests for patients on disease-modifying arthritis drugs.

Remind yourself of the monitoring requirements for disease-modifying antirheumatic drugs with the MIMS DMARDs table

This table summarises the ongoing tests advised for patients taking the DMARDs azathioprine, chloroquine, ciclosporin, hydroxychloroquine, leflunomide, methotrexate, penicillamine, sodium aurothiomalate (gold) or sulfasalazine.     

Tests include:

  • full blood counts
  • liver function tests
  • ophthalmological examination
  • renal function and urinalysis
  • blood pressure
  • serum lipids
  • chest x-ray
  • plasma drug levels

The recommended frequency of testing is also noted in the table.

Brand names link through to the full MIMS entries for more detailed prescribing information on each product.

Go to the MIMS DMARDs table

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Reduce insulin doses carefully when starting GLP-1 agonists, MHRA advises

Reduce insulin doses carefully when starting GLP-1 agonists, MHRA advises

A careful stepwise approach is needed when reducing...

Prescribers advised not to use newer anticoagulants in patients with antiphospholipid syndrome
Drug shortages - live tracker

Drug shortages - live tracker

Check on the latest drug supply issues with MIMS' shortages...

Novel MS drug gains NICE approval

Novel MS drug gains NICE approval

New NICE guidance recommends ocrelizumab (Ocrevus)...